Total Payments
$11,976
2024 Payments
$253.95
Companies
30
Transactions
68
Medicare Patients
15,832
Medicare Billing
$2.0M
Payment Breakdown by Category
Consulting$9,650 (80.6%)
Food & Beverage$1,307 (10.9%)
Travel$903.05 (7.5%)
Education$116.51 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $9,650 | 3 | 80.6% |
| Food and Beverage | $1,307 | 58 | 10.9% |
| Travel and Lodging | $903.05 | 4 | 7.5% |
| Education | $116.51 | 3 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $4,459 | 16 | $0 (2024) |
| Amgen Inc. | $3,570 | 1 | $0 (2020) |
| Ipsen Biopharmaceuticals, Inc | $2,915 | 2 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $167.12 | 8 | $0 (2024) |
| Gilead Sciences, Inc. | $101.94 | 6 | $0 (2022) |
| Janssen Products, LP | $99.95 | 1 | $0 (2017) |
| PFIZER INC. | $80.32 | 5 | $0 (2024) |
| Astellas Pharma US Inc | $65.15 | 3 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $64.68 | 3 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $55.06 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $253.95 | 12 | AstraZeneca Pharmaceuticals LP ($42.64) |
| 2023 | $189.51 | 10 | Celgene Corporation ($61.59) |
| 2022 | $92.61 | 5 | Gilead Sciences, Inc. ($53.42) |
| 2021 | $369.66 | 21 | Novartis Pharmaceuticals Corporation ($76.44) |
| 2020 | $3,585 | 2 | Amgen Inc. ($3,570) |
| 2019 | $2,898 | 2 | Ipsen Biopharmaceuticals, Inc ($2,880) |
| 2018 | $4,419 | 12 | Celgene Corporation ($4,364) |
| 2017 | $168.41 | 4 | Janssen Products, LP ($99.95) |
All Payment Transactions
68 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.09 | General |
| Category: Hematology | ||||||
| 11/11/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $20.87 | General |
| Category: ONCOLOGY | ||||||
| 10/08/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: Oncology | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: Oncology | ||||||
| 09/10/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: ONCOLOGY | ||||||
| 08/07/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Oncology | ||||||
| 04/23/2024 | GENZYME CORPORATION | CABLIVI (Biological) | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: Hematology | ||||||
| 03/05/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $28.00 | General |
| Category: Oncology | ||||||
| 03/05/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 02/20/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $16.62 | General |
| Category: ONCOLOGY | ||||||
| 02/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: ONCOLOGY | ||||||
| 01/23/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $29.81 | General |
| Category: Oncology | ||||||
| 11/28/2023 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2023 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: Oncology | ||||||
| 10/24/2023 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $23.12 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.04 | General |
| Category: Hematology | ||||||
| 07/19/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $33.54 | General |
| Category: ONCOLOGY | ||||||
| 07/12/2023 | SOBI, INC | Doptelet (Drug) | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 04/25/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.04 | General |
| Category: Hematology | ||||||
| 02/28/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.47 | General |
| Category: Hematology | ||||||
| 02/14/2023 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $19.15 | General |
| Category: Oncology | ||||||
| 01/10/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.04 | General |
| Category: Hematology | ||||||
| 11/22/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: ONC | ||||||
| 11/08/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $22.15 | General |
| Category: ONC | ||||||
| 10/04/2022 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 586 | 1,148 | $345,029 | $92,608 |
| 2022 | 8 | 308 | 540 | $143,424 | $46,536 |
| 2021 | 25 | 959 | 2,215 | $162,670 | $52,088 |
| 2020 | 103 | 13,979 | 277,363 | $9.3M | $1.8M |
Total Patients
15,832
Total Services
281,266
Medicare Billing
$2.0M
Procedure Codes
146
All Medicare Procedures & Services
146 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 88 | 334 | $127,871 | $35,358 | 27.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 125 | 283 | $79,164 | $19,783 | 25.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 133 | 207 | $40,964 | $8,982 | 21.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 87 | 87 | $33,000 | $7,797 | 23.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 36 | 36 | $17,312 | $5,013 | 29.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 34 | 80 | $14,248 | $4,875 | 34.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 51 | $12,999 | $4,771 | 36.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 24 | 27 | $9,231 | $2,763 | 29.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 18 | $8,027 | $2,343 | 29.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 18 | 25 | $2,213 | $922.61 | 41.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 61 | 160 | $54,747 | $18,515 | 33.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 76 | 139 | $35,495 | $10,772 | 30.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 50 | 50 | $17,270 | $5,365 | 31.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 60 | 78 | $14,046 | $4,076 | 29.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 37 | $8,293 | $2,949 | 35.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 41 | $6,613 | $2,323 | 35.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 18 | 19 | $5,634 | $2,043 | 36.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 13 | 16 | $1,326 | $493.12 | 37.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 61 | 121 | $28,551 | $11,098 | 38.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 34 | 34 | $14,280 | $6,008 | 42.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 44 | 44 | $14,696 | $5,639 | 38.4% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 15 | 45 | $15,300 | $5,359 | 35.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 53 | 82 | $14,550 | $5,115 | 35.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 17 | 26 | $10,250 | $3,231 | 31.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2021 | 94 | 241 | $7,514 | $2,526 | 33.6% |
About Zulfiqar Malik, M.D., PHD
Zulfiqar Malik, M.D., PHD is a Hematology & Oncology healthcare provider based in Marietta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1841364908.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Zulfiqar Malik, M.D., PHD has received a total of $11,976 in payments from pharmaceutical and medical device companies, with $253.95 received in 2024. These payments were reported across 68 transactions from 30 companies. The most common payment nature is "Consulting Fee" ($9,650).
As a Medicare-enrolled provider, Malik has provided services to 15,832 Medicare beneficiaries, totaling 281,266 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 146 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Marietta, GA
- Active Since 11/20/2006
- Last Updated 04/26/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1841364908
Products in Payments
- ONIVYDE (Drug) $2,880
- ZYTIGA (Drug) $99.95
- Trodelvy (Drug) $90.02
- REBLOZYL (Biological) $75.68
- LUTATHERA (Drug) $62.16
- XARELTO (Drug) $55.06
- MEKINIST (Drug) $53.80
- IMBRUVICA (Drug) $46.83
- clonoSEQ (Device) $39.74
- XTANDI (Drug) $37.51
- Somatuline Depot (Drug) $35.49
- KISQALI (Drug) $32.01
- XALKORI (Drug) $30.59
- Padcev (Drug) $28.00
- TAGRISSO (Drug) $23.70
- Enhertu (Drug) $23.37
- CABLIVI (Biological) $22.88
- KEYTRUDA (Biological) $22.38
- XPOVIO (Drug) $21.69
- EPKINLY (Drug) $20.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Marietta
Dr. Steven Mccune, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $492,856
Hematology & Oncology $492,856
Dr. Gena Volas-Redd, Md, MD
Hematology & Oncology — Payments: $115,709
Hematology & Oncology $115,709
Dr. John French, Md, MD
Hematology & Oncology — Payments: $70,611
Hematology & Oncology $70,611
Dr. Louis Garrot, M.d, M.D
Hematology & Oncology — Payments: $57,738
Hematology & Oncology $57,738
Vivek Abhyankar, Md, MD
Hematology & Oncology — Payments: $53,680
Hematology & Oncology $53,680
Dr. Dean Kirkel, Md, MD
Hematology & Oncology — Payments: $53,593
Hematology & Oncology $53,593